Summary
A medRxiv preprint reports that medetomidine’s co-presence in fentanyl samples submitted to a Southern California drug-checking programme rose from about 6% in May 2025 to about 25% by August 2026. The study analysed drug samples, not patient outcomes, and has not yet undergone peer review.
A medRxiv preprint reports that medetomidine became increasingly common in fentanyl samples submitted to a community drug-checking programme in Southern California. Its measured co-presence with fentanyl rose from about 6% in May 2025, when it was first detected, to about 25% by August 2026. The study analysed drug products rather than people, so these figures describe the samples checked—not the share of fentanyl in circulation overall or the rate of harm among users.
What the drug-checking analysis found
Anonymous participants voluntarily submitted drug products to the programme between 2023 and 2026. Researchers screened samples using direct-analysis-in-real-time mass spectrometry (DART-MS), a technique for identifying chemical substances. They used liquid chromatography tandem mass spectrometry (LC-MS/MS) to quantify medetomidine in a subset, and analysed the enantiomers—the two mirror-image forms of the molecule—in a smaller subset.
The researchers report that medetomidine’s quarterly prevalence among fentanyl samples increased from approximately 6% in May 2025 to approximately 25% by August 2026. The average measured concentration was 0.4% by mass. Fentanyl was the most common substance detected alongside medetomidine; lidocaine and xylazine were among the other co-detected substances.
All 13 samples tested for enantiomer composition contained racemic medetomidine, meaning a mixture of the molecule’s two mirror-image forms. The authors say this finding suggests the medetomidine was not diverted from human pharmaceutical or medical supplies. That interpretation comes from the analysed subset, rather than every sample in the study.
Why the finding matters
Medetomidine is a potent sedative. Its increasing detection alongside fentanyl matters because a small mass fraction may still represent a physiologically significant amount: the authors say a concentration below 1.5% is likely to be significant, while the average they measured was 0.4%. The study also found xylazine in some of the same samples, indicating that medetomidine was not the only sedative detected in this supply.
The results provide a time series from a community-based drug-checking programme, documenting a rapid rise in medetomidine detection in the samples it received. Such monitoring can identify changes in the composition of submitted drugs and help public-health teams track emerging adulterants.
How to interpret the results
This is a preprint: the findings have been posted on medRxiv and have not yet undergone peer review. The study’s prevalence estimates apply to fentanyl samples submitted to this particular Southern California programme. The abstract does not provide the total number of samples or the counts underlying each percentage, so the estimates should be read as programme-specific signals of a changing local drug supply.
The analysis concerns chemical composition, not clinical outcomes. It does not measure how many people used the sampled drugs or how medetomidine affected them. The reported rise is therefore evidence of increasing detection in checked samples, rather than a direct measure of overdose risk or population-wide prevalence.